EP0927718A1 — Quinolinone derivative, method for preparing the same, and anti-allergic agent
Assigned to DIC Corp · Expires 1999-07-07 · 27y expired
What this patent protects
The present invention relates to a simple method for preparing a quinolinone derivative, which is effective as a medicine, e.g., as an agent for treating allergic diseases and the like; novel amide derivatives effective as an intermediate in the method; novel quinolinone derivati…
USPTO Abstract
The present invention relates to a simple method for preparing a quinolinone derivative, which is effective as a medicine, e.g., as an agent for treating allergic diseases and the like; novel amide derivatives effective as an intermediate in the method; novel quinolinone derivatives obtained according to the method; and an anti-allergic agent contaiirng a quinolinone derivative and/or physiological salt of the same as the active ingredients. The quinolinone derivative is expressed by the following general formula (II); and the method is characterized in that an amide derivative, expressed by the following general formula (I), is reacted with a basic agent, followed by intramolecular ring formation: General Formula (I) [wherein, R 1 represents a hydrogen atom, an alkyl group, an alkyl group containing a hydroxyl group, an alkenyl group, or an aryl group; R 2 represents an alkyl group, an alkenyl group, an aryl group, or an aralkyl group; R 3 represents a reactive carboxyl group; and R 4 to R 7 represent, respectively and independently, a hydrogen atom, a hydroxyl group, an alkyl group, an alkoxy group, an alkenyl group, an alkenyloxy group, an aryl group, an aryloxy group, an aralkyloxy group, a R 8 R 9 N group (wherein, R 8 and R 9 represent, respectively and independently, a hydrogen atom, an alkyl group, an aikenyl group, an aralkyl group, or an acyl group), a nitro group, or a R 10 OOC group (wherein, R 10 represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, or an aralkyl group)]. General Formula (II) [wherein, R 1 , R 2 and R 4 to R 7 represent, respectively, the same constituents as described in general formula (I)].
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.